Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Treace Medical Concepts (NasdaqGS: TMCI), a pioneer in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
CEO John T. Treace will deliver a presentation on Tuesday, January 14, 2025, at 9:00 am PT. The company will provide a live webcast of the fireside chat, which will be accessible through their investor relations website at https://investors.treace.com/.
The company maintains regular updates for investors through their website's Investor Relations section at www.treace.com, where important information is routinely posted for stakeholders and potential investors.
Positive
- None.
Negative
- None.
PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When is Treace Medical Concepts (TMCI) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Treace Medical's (TMCI) J.P. Morgan Healthcare Conference presentation?
What surgical procedures does Treace Medical (TMCI) specialize in?
Where can investors find important information about Treace Medical (TMCI)?
